Search

Displaying results 5321 - 5330 of 10000 in total
  1. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  2. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  3. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. … It has also been undergone research as a potential anti-Parkinsonian drug for humans.

  4. Drug

    Anisodamine

    go.drugbank.com/drugs/DB11785
    Investigational

    Anisodamine has been investigated for the treatment of Intestinal Diseases.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Rufloxacin

    go.drugbank.com/drugs/DB13772
    Investigational

    Rufloxacin is a quinolone antibiotic.[A31894]

    Categories: Topoisomerase II Inhibitors
  6. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

  7. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  8. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  9. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

  10. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.